OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers
Retrovirology volume 6, Article number: O31 (2009)
In healthy volunteers, we sought to determine the safety, tolerability, and immunogenicity of ADVAX, a subtype B'/C, DNA-based, multigenic, HIV-1 vaccine candidate, when injected intramuscularly immediately followed by in vivo electroporation (EP) using the TriGrid™ Delivery System.
Forty healthy volunteers aged 18–60 were enrolled in a double blind randomized phase-I trial. Eight volunteers each received either low dose (LD, 0.2 mg); mid dose (MD, 1.0 mg); or high dose (HD, 4.0 mg) ADVAX or saline placebo via EP. Another eight volunteers received 4.0 mg ADVAX intramuscularly (IM). Vaccinations were given at weeks 0 and 8. The protocol was subsequently amended to administer a third dose of HD EP/placebo at week 36 to volunteers receiving either HD ADVAX via EP (n = 8) or placebo via EP (n = 3). Total study follow-up is 14 months.
There have been no vaccine or device related serious adverse events to date. After two vaccinations in all subjects, the IFNg ELISPOT response rates were IM: 1/8 (13%), LD-EP: 3/8 (38%) MD-EP: 7/8 (88%) and HD-EP: 6/8 (75%). In the same order, the mean (range) response to peptide pools spanning all antigens was 72, 120 (70–193), 151 (53–440), and 141 (59–336) SFC/million PBMCs. The breadth of the response improved with EP and increasing dosage, with responses to 1, 1, 3, and 4 of the 4 ADVAX gene products. ICCS analysis of ELISPOT responders revealed a balanced CD4+/CD8+ response. There were no responses to placebo, by definition. An analysis of responses after the third vaccination in the high dosage group is ongoing.
This study is the first demonstration in healthy volunteers that EP in vivo is safe, tolerable, and effective in improving the magnitude and breadth of cellular immune responses to a DNA-based vaccine.
About this article
Cite this article
Vasan, S., Hurley, A., Schlesinger, S. et al. OA05-01. In vivo electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers. Retrovirology 6 (Suppl 3), O31 (2009). https://doi.org/10.1186/1742-4690-6-S3-O31